Asahi Kasei Medical
  • Site Map
  • Contact Us
  • Font size: Small
  • Font size: Medium
  • Font size: Large
  • Home
  • Our Approach to Business
  • Corporate Information
  • News
  • Products
  • Patients and Families

References by Products

Literature containing information about our products for therapeutic apheresis.

Plasmaflo OP references

Featured references

Hirata et al.
Plasma separator Plasmaflo OP.
Ther Apher Dial. 7:64-8, 2003.
Nagano et al.
Comparative study of polyethylene plasma separator sterilized by ethylene oxide and gamma rays.
Jpn J Aspheresis. 16:297-8, 1997.
Hirata et al.
Plasma separator Plasmaflo OP.
Ther Apher Dial. 7:64-8, 2003.
Akioka et al.
A case of chronic relapsing ANCA-associated microscopic polyangiitis successfully treated with plasma exchange.
Ther Apher Dial. 8:223-6, 2004.
Nakagawa et al.
A case report of an adult with severe hyperlipidemia during acute lymphocytic leukemia induction therapy successfully treated with plasmapheresis.
Ther Apher Dial. 12:509-13, 2008.
Kawano et al.
Therapeutic modality of 11 patients with TTP in a single institution in Miyazaki from 2000 to 2011.
Intern Med. 52:1883-91, 2013.

Top of page

Cascadeflo EC references

Featured references

Julius et al.
Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis--comparison of performance characteristics with DALI and Lipidfiltration.
J Clin Apher. 22:215-23, 2007.
Julius et al.
Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP.
Int J Artif Organs. 25:1180-8, 2002.
Klingel et al.
From membrane differential filtration to lipidfiltration: technological progress in low-density lipoprotein apheresis.
Ther Apher Dial. 7:350-8, 2003.
Klingel et al.
Lipidfiltration - safe and effective methodology to perform lipid-apheresis.
Transfusion and Apheresis Science. 30:245-254, 2004.
Taniguchi et al.
Impact of double-filtration plasmapheresis in combination with interferon and ribavirin in living donor liver transplant recipients with hepatitis C.
Transplantation. 81:1747-9, 2006.
Fujiwara et al.
Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load.
Hepatol Res. 37:701-10, 2007.
Yu et al.
A controlled study of double filtration plasmapheresis in the treatment of active rheumatoid arthritis.
J Clin Rheumatol. 13:193-8, 2007.
Julius et al.
Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis--comparison of performance characteristics with DALI and Lipidfiltration.
J Clin Apher. 22:215-23, 2007.
Kaneko et al.
Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C.
Hepatol Res. 40:1072-1081, 2010.
Fernández-Fuertes et al.
Low-density lipoprotein apheresis using double filtration plasmapheresis: 27-month use in a child with homozygous familial hypercholesterolemia.
Ther Apher Dial. 14:484-5, 2010.
Liu et al.
Successful treatment of patients with systemic lupus erythematosus complicated with autoimmune thyroid disease using double-filtration plasmapheresis: a retrospective study.
J Clin Apher. 26:174-80, 2011.
Hirai et al.
Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection.
Transpl Int. 25:925-34, 2012.
Lumlertgul et al.
Double filtration plasmapheresis in different diseases in Thailand.
Ther Apher Dial. 17:99-116, 2013.
Leebmann et al.
Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease: Prospective Observational Multicenter Study.
Circulation. 128:2567-76, 2013.
Sugimoto et al.
Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy.
Dig Dis. 31:434-9, 2013.

Top of page

IMMUSORBA TR references

Featured references

Hirata et al.
IMMUSORBA TR and PH.
Ther Apher Dial. 7:85-90, 2003.
Yoshida et al.
IMMUSORBA TR and IMMUSORBA PH: Basics of design and features of functions.
Ther Apher. 4:127-34, 2000.
Yoshida et al.
IMMUSORBA TR and IMMUSORBA PH: Basics of design and features of functions.
Ther Apher. 4:127-34, 2000.
Haupt et al.
Apheresis and selective adsorption plus immunoglobulin treatment in Guillain-Barré syndrome.
Ther Apher. 4:198-200, 2000.
Ota et al.
Neutrophil activation in immunoadsorption.
Ther Apher. 4:229-34, 2000.
Yang et al.
Plasma adsorption in critical care.
Ther Apher. 6:184-8, 2002.
Hirata et al.
IMMUSORBA TR and PH.
Ther Apher Dial. 7:85-90, 2003.
Beige et al.
Immunoadsorption with tryptophan adsorbers for successful treatment of late steroid-refractory recurrent focal glomerulosclerosis.
Am J Transplant. 3:1459, 2003.
Splendiani et al.
Plasmaperfusion on triptophan columns can improve the clinical outcome of patients affected with myasthenia gravis.
Artif Cells Blood Substit Immobil Biotechnol. 31:69-79, 2003.
Luftl et al.
Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber.
Br J Dermatol. 149:598-605, 2003.
Okamiya et al.
Tryptophan-immobilized column-based immunoadsorption as the choice method for plasmapheresis in Guillain-Barre syndrome.
Ther Apher Dial. 8:248-53, 2004.
Seta et al.
Factors influencing outcome in Guillain-Barré Syndrome: comparison of plasma adsorption against other treatments.
Clin Neurol Neurosurg. 107:491-6, 2005.
Arakawa et al.
Immunoadsorption therapy for a child with Guillain-Barré syndrome subsequent to Mycoplasma infection: a case study.
Brain Dev. 27:431-3, 2005.
Wagner et al.
[Long-term treatment of refractory myasthenia gravis with immunoadsorption].
Dtsch Med Wochenschr. 133:2377-82, 2008. German
Wenning et al.
Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
N Engl J Med. 361:1075-80, 2009.
Galldiks et al.
Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment.
Eur Neurol. 66:183-9, 2011.
Nagatomo et al.
Specific immunoadsorption therapy using a tryptophan column in patients with refractory heart failure due to dilated cardiomyopathy.
J Clin Apher. 26:1-8, 2011.
Nagane et al.
Early aggressive treatment strategy against myasthenia gravis.
Eur Neurol. 65:16-22, 2011.
Köhler et al.
A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.
J Clin Apher. 26:347-55, 2011.
Trebst et al.
Immunoadsorption therapy for steroid-unresponsive relapses in patients with multiple sclerosis.
Blood Purif. 33:1-6, 2012.
Koziolek et al.
Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis.
J Neuroinflammation. 26;9:80, 2012.
Koziolek et al.
Immunoadsorption in steroid-refractory multiple sclerosis.
Atheroscler Suppl. 14:175-8, 2013.
Klingel et al.
Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies--perspectives for immunoadsorption.
Atheroscler Suppl. 14:161-5, 2013.
Heigl et al.
Immunoadsorption in steroid-refractory multiple sclerosis: clinical experience in 60 patients.
Atheroscler Suppl. 14:167-73, 2013.
Yonee et al.
Association of acute cerebellar ataxia and human papilloma virus vaccination: a case report.
Neuropediatrics. 44:265-7, 2013.

Top of page

IMMUSORBA PH references

Featured references

Hirata et al.
IMMUSORBA TR and PH.
Ther Apher Dial. 7:85-90, 2003.
Yoshida et al.
IMMUSORBA TR and IMMUSORBA PH: Basics of design and features of functions.
Ther Apher. 4:127-34, 2000.
Gaubitz et al.
Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus.
J Autoimmun. 11:495-501, 1998.
Yoshida et al.
IMMUSORBA TR and IMMUSORBA PH: Basics of design and features of functions.
Ther Apher. 4:127-34, 2000.
Yang et al.
Plasma adsorption in critical care.
Ther Apher. 6:184-8, 2002.
Hirata et al.
IMMUSORBA TR and PH.
Ther Apher Dial. 7:85-90, 2003.
Sugimoto et al.
Immunoadsorption plasmapheresis using a phenylalanine column as an effective treatment for lupus nephritis.
Ther Apher Dial. 10:187-92, 2006.
Yamaji et al.
Long-term clinical outcomes of synchronized therapy with plasmapheresis and intravenous cyclophosphamide pulse therapy in the treatment of steroid-resistant lupus nephritis.
Ther Apher Dial. 12:298-305, 2008.
Loo et al.
Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis.
Transfus Apher Sci. 43:335-40, 2010.

Top of page

PLASORBA BR references

Featured references

Takenaka Y.
Bilirubin adsorbent column for plasma perfusion.
Ther Apher. 2:129-33, 1998.
Takenaka Y.
Bilirubin adsorbent column for plasma perfusion.
Ther Apher. 2:129-33, 1998.
Senf et al.
Bilirubin-adsorption in 23 critically ill patients with liver failure.
Int J Artif Organs. 27:717-22, 2004.
Adani et al.
Selective bilirubin removal by plasma treatment with Plasorba BR-350 for early cholestatic graft dysfunction.
Transplant Proc. 39:1904-6, 2007.
Krawczyk et al.
Prolonged cholestasis triggered by hepatitis A virus infection and variants of the hepatocanalicular phospholipid and bile salt transporters.
Ann Hepatol. 11:710-4, 2012.

Top of page

Rheofilter references

Featured references

Koss et al.
Prospective, randomized, controlled clinical study evaluating the efficacy of Rheopheresis for dry age-related macular degeneration. Dry AMD treatment with Rheopheresis Trial-ART.
Graefes Arch Clin Exp Ophthalmol. 247:1297-306, 2009.
Koss et al.
Prospective, randomized, controlled clinical study evaluating the efficacy of Rheopheresis for dry age-related macular degeneration. Dry AMD treatment with Rheopheresis Trial-ART.
Graefes Arch Clin Exp Ophthalmol. 247:1297-306, 2009.

Top of page

CUREFLO references

Featured references

Floris et al.
Evaluation of a new polysulfone hemofilter for continuous renal replacement therapy.
Blood Purif. 32:133-8, 2011.
Floris et al.
Evaluation of a new polysulfone hemofilter for continuous renal replacement therapy.
Blood Purif. 32:133-8, 2011.

Top of page

Cellsorba EX references

Featured references

Shibata et al.
Cellsorba.
Therap Apher Dial. 7:44-7, 2003.
Matsumoto et al.
Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis: a multicenter prospective open-label study.
Ther Apher Dial. 12:484-90, 2008.
Nagase et al.
Complications of Leukocytapheresis.
Ther Apher. 2:120-4, 1998.
Kosaka et al.
Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease.
Intern Med. 38:102-11, 1999.
Hidaka et al.
Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis.
J Clin Apheresis. 16:74-81, 2001.
Yamaji et al.
Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers.
Ther Apher. 6:402-12, 2002.
Shibata et al.
Cellsorba.
Therap Apher Dial. 7:44-7, 2003.
Sawada et al.
Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column.
Current Pharmaceutical Design 9:307-21, 2003.
Fukunaga et al.
Poorly controlled ulcerative colitis treated by colectomy during remission induced by extracorporeal leukocyte removal therapy.
J Gastroenterol. 38:684-9, 2003.
Kohgo et al.
Leukocytapheresis for treatment of IBD.
J Gastroenterol. 38 Suppl 15:51-4, 2003.
Sawada K.
Leukocytapheresis as an adjunct to conventional medication for inflammatory bowel disease.
Dis Colon Rectum. 46 Suppl: S66-77, 2003.
Andoh et al.
Suppression of interleukin-1beta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis.
J Gastroenterol. 39:1150-7, 2004.
Sawada et al.
Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment.
Am J Gastroenterol. 100:1362-9, 2005.
Sawada et al.
Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon.
Dig Dis Sci. 50:767-73, 2005.
Ashizuka et al.
Leukocytapheresis for ulcerative colitis: a comparative study of anticoagulant (nafamostat mesilate vs. dalteparin sodium) for reducing clinical complications.
Ther Apher Dial. 10:54-8, 2006.
Sandborn WJ.
Preliminary data on the use of apheresis in inflammatory bowel disease.
Inflamm Bowel Dis. 12 Suppl 1:S15-21, 2006.
Matsumoto et al.
Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis: a multicenter prospective open-label study.
Ther Apher Dial. 12:484-90, 2008.
Mitsuyama et al.
Mobilization of bone marrow cells by leukocytapheresis in patients with ulcerative colitis.
Ther Apher Dial. 12:271-7, 2008.
Mitsuyama et al.
Recent understanding of leukocytapheresis (LCAP) for the treatment of inflammatory bowel disease.
Curr Pharm Des. 15:2110-9, 2009.
Mitsuyama et al.
Therapeutic leukocytapheresis in inflammatory bowel disease: clinical efficacy and mechanisms of action.
Cytotherapy. 11:229-37, 2009.
Muratov et al.
Safety and tolerability of a modified filter-type device for leukocytapheresis using ACD-A as anticoagulant in patients with mild to moderately active ulcerative colitis. Results of a pilot study.
J Clin Apher. 25:287-93, 2010.
Ashida et al.
A multicenter study of the efficacy and safety of leukocytapheresis therapy without concomitant systemic steroid treatment in patients with active ulcerative colitis.
Transfus Apher Sci. 44:113-7, 2011.
Fukunaga et al.
Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with Cellsorba in patients with active ulcerative colitis.
J Clin Apher. 26:326-31, 2011.
Okuyama et al.
Multicenter prospective study for clinical and endoscopic efficacies of leukocytapheresis therapy in patients with ulcerative colitis.
Scand J Gastroenterol. 48:412-8, 2013.

Top of page

Contact Us

Please feel free to send us any questions you may have about our products and support.

Contact Us

Your Voice

Share your feelings and experiences when using our products.

Your Voice
Note: It might be required in your country that medical devices shall be officially registered and/or approved by an authorized organization. Please contact our representative in your region or contact us to confirm whether the listed products are approved for use. These information may contain general information on medical-related topics and is not meant to provide specialist advice or instructions concerning the products and services sold by Asahi Kasei Medical. Please contact us directly for special inquiries. You should not use this information for diagnosing a health problem or disease but should always consult your own physician.Contact us

Top of page